Mitesh A Desai1, Dancun O Okal2, Charles E Rose3, Richard Ndivo2, Boaz Oyaro2, Fredrick O Otieno2, Tiffany Williams4, Robert T Chen3, Clement Zeh3, Taraz Samandari3. 1. Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: mdesai1@cdc.gov. 2. Kenya Medical Research Institute, Kisumu, Kenya. 3. Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. ICF International, Assigned to Division of HIV/AIDS Prevention, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: HIV disease staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiation of antiretroviral treatment (ART). Point-of-care CD4 cell counts can improve linkage to HIV care among people living with HIV, but its effect has not been assessed with a randomised controlled trial in the context of home-based HIV counselling and testing (HBCT). METHODS: We did a two-arm, cluster-randomised, controlled efficacy trial in two districts of western Kenya with ongoing HBCT. Housing compounds were randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or standard-of-care (318 compounds with 353 participants) CD4 cell counts done at one of three referral laboratories serving the study catchment area. In each compound, we enrolled people with HIV not engaged in care in the previous 6 months. All participants received post-test counselling and referral for HIV care. Point-of-care test participants received additional counselling on the result, including ART eligibility if CD4 was less than 350 cells per μL, the cutoff in Kenyan guidelines. Participants were interviewed 6 months after enrolment to ascertain whether they sought HIV care, verified through chart reviews at 23 local clinics. The prevalence of loss to follow-up at 6 months (LTFU) was listed as the main outcome in the study protocol. We analysed linkage to care at 6 months (defined as 1-LTFU) as the primary outcome. All analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT02515149. FINDINGS:We enrolled 770 participants between July 1, 2013, and Feb 28, 2014. 692 (90%) had verified linkage to care status and 78 (10%) were lost to follow-up. Of 371 participants in the point-of-care group, 215 (58%) had linked to care within 6 months versus 108 (34%) of 321 in the standard-of-care group (Cox proportional multivariable hazard ratio [HR] 2·14, 95% CI 1·67-2·74; log rank p<0·0001). INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT setting doubled linkage to care and thereby improved ART initiation. Given the substantial economic and logistic hindrances to providing ART for all people with HIV in resource-limited settings in the near term, point of care CD4 cell counts might have a role in prioritising care and improving linkage to care. FUNDING: US Centers for Disease Control and Prevention.
RCT Entities:
BACKGROUND:HIV disease staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiation of antiretroviral treatment (ART). Point-of-care CD4 cell counts can improve linkage to HIV care among people living with HIV, but its effect has not been assessed with a randomised controlled trial in the context of home-based HIV counselling and testing (HBCT). METHODS: We did a two-arm, cluster-randomised, controlled efficacy trial in two districts of western Kenya with ongoing HBCT. Housing compounds were randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or standard-of-care (318 compounds with 353 participants) CD4 cell counts done at one of three referral laboratories serving the study catchment area. In each compound, we enrolled people with HIV not engaged in care in the previous 6 months. All participants received post-test counselling and referral for HIV care. Point-of-care test participants received additional counselling on the result, including ART eligibility if CD4 was less than 350 cells per μL, the cutoff in Kenyan guidelines. Participants were interviewed 6 months after enrolment to ascertain whether they sought HIV care, verified through chart reviews at 23 local clinics. The prevalence of loss to follow-up at 6 months (LTFU) was listed as the main outcome in the study protocol. We analysed linkage to care at 6 months (defined as 1-LTFU) as the primary outcome. All analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT02515149. FINDINGS: We enrolled 770 participants between July 1, 2013, and Feb 28, 2014. 692 (90%) had verified linkage to care status and 78 (10%) were lost to follow-up. Of 371 participants in the point-of-care group, 215 (58%) had linked to care within 6 months versus 108 (34%) of 321 in the standard-of-care group (Cox proportional multivariable hazard ratio [HR] 2·14, 95% CI 1·67-2·74; log rank p<0·0001). INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT setting doubled linkage to care and thereby improved ART initiation. Given the substantial economic and logistic hindrances to providing ART for all people with HIV in resource-limited settings in the near term, point of care CD4 cell counts might have a role in prioritising care and improving linkage to care. FUNDING: US Centers for Disease Control and Prevention.
Authors: Paul K Drain; Jienchi Dorward; Andrew Bender; Lorraine Lillis; Francesco Marinucci; Jilian Sacks; Anna Bershteyn; David S Boyle; Jonathan D Posner; Nigel Garrett Journal: Clin Microbiol Rev Date: 2019-05-15 Impact factor: 26.132
Authors: Nneoma E Okonkwo; Alexander Blum; Nikita Viswasam; Elizabeth Hahn; Sofia Ryan; Gnilane Turpin; Carrie E Lyons; Stefan Baral; Bhakti Hansoti Journal: AIDS Behav Date: 2022-01-28
Authors: Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong Journal: Clin Microbiol Rev Date: 2018-11-28 Impact factor: 26.132
Authors: Brendan Maughan-Brown; Sean Beckett; Ayesha B M Kharsany; Cherie Cawood; David Khanyile; Lara Lewis; Atheendar Venkataramani; Gavin George Journal: AIDS Care Date: 2020-02-09
Authors: Olga Tymejczyk; Ellen Brazier; Constantin Yiannoutsos; Kara Wools-Kaloustian; Keri Althoff; Brenda Crabtree-Ramírez; Kinh Van Nguyen; Elizabeth Zaniewski; Francois Dabis; Jean d'Amour Sinayobye; Nanina Anderegg; Nathan Ford; Radhika Wikramanayake; Denis Nash Journal: PLoS Med Date: 2018-03-23 Impact factor: 11.069
Authors: Robert A Domaoal; Katrina Sleeman; Souleymane Sawadogo; Tafadzwa Dzinamarira; Ndahafa Frans; Saara P Shatumbu; Ligamena N Kakoma; Terthu K Shuumbwa; Mackenzie Hurlston Cox; Sally Stephens; Lydia Nisbet; Melissa Metz; Suzue Saito; Daniel B Williams; Andrew C Voetsch; Hetal K Patel; Bharat S Parekh; Yen T Duong Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.771
Authors: Vairamohan Vidhyavathi; Hussain Syed Iqbal; Kannaiyan Kanthamani; Sunil Suhas Solomon; Paneerselvam Nandagopal; Stanley Luchters; Minh D Pham; James Forbes; Suzanne M Crowe; Christopher McMurran; David A Anderson; Pachamuthu Balakrishnan Journal: J Int Med Res Date: 2020-09 Impact factor: 1.671